Vasomedical, a maker of medical devices and seller of diagnostic imaging products, reports that its EECP Therapy devices for the treatment of vascular endothelial dysfunction and for the prevention of onset and progression of cerebral, coronary, and peripheral vascular diseases will be featured at the Stony Brook Medicine’s new Center for Cardiovascular Wellness and Preventive Research.
EECP Therapy is an FDA-cleared, non-invasive therapeutic device manufactured by Vasomedical, designed to moderate the workload of the heart while increasing blood flow to the coronary arteries and other organs of the body. By focusing on this EECP Therapy, researchers at the new center will conduct research into cardiovascular health and seek to identify and develop new options to treat and prevent coronary artery disease, heart failure, and Alzheimer’s disease.
In addition, the center will be used to conduct exploratory research of the use of EECP Therapy as a means of preventing muscle soreness and injury in elite athletes.
Dr. Michael Poon, a professor of Emergency Medicine, Medicine (Cardiology), and Radiology, and Director of Advanced Cardiovascular Imaging at Stony Brook Medicine, will lead the research efforts.
“At Vasomedical, we have been proponents of EECP Therapy for almost 20 years, seeing incredible benefits to many different patient populations. Stony Brook University was among the first in the United States to adopt EECP Therapy as a noninvasive treatment for cardiac ailments and has participated in many published studies. We are grateful for Stony Brook University and Dr. Poon’s continued support and commitment to the research with our innovative devices,” Dr. John Hui, Chief Technology Officer of Vasomedical stated in the press release. “We look forward to seeing the results of their studies, and are pleased that such a reputable institution is working to raise public awareness and support a technology with the potential to revolutionize the cardiovascular health industry.”
For more information, visit www.vasomedical.com
Let us hear your thoughts below:
